Campath-1H is a new treatment for Multiple Sclerosis or MS. The scientific name for Campath is alemtuzumab and the drug will in future be marketed as Lemtrada. It is now approved for use in MS in the USA and Europe. The drug is a monoclonal antibody designed to target that part of the immune system which is assumed to be harming people with MS (PwMS).  It has been developed for a number of years, and has already been used as a treatment for B-cell chronic lymphocytic leukaemia.


Approval has now been granted from the FDA in America and the EMA in Europe.

My diary has been updated as of November 2016. The gap between updates is simply due to the lack of any real news.

I have also updated the diary to reflect the name change of this drug to Lemtrada, so that future patients may still find this site.


I am not a doctor, but a person with MS who has undergone this treatment. This site is no substitute for professional medical advice, but merely a tool for those seeking more information on this subject. Campath (or Lemtrada, alemtuzumab) is a powerful drug, and should only be considered as a treatment option after extensive consultations between a patient and their own medical practitioners.

Links are provided to sites outside this website. I am not responsible for the content on those external sites, nor do I endorse them. They are provided for information only.

Good luck in your fight with MS.

David Sturt  2003-2016